These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17908180)

  • 1. A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy.
    Falchi L; Capello D; Palumbo B; Rauco A; Emili R; Cianciulli M; Pace R; Capparella V; Liberati F; Liberati AM
    Eur J Haematol; 2007 Nov; 79(5):455-61. PubMed ID: 17908180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-6-positive classical Hodgkin's lymphoma co-occurring with plasma cell type of Castleman's disease: report of a case.
    Momoi A; Kojima M; Sakai T; Ajiro J; Isahai N; Nagai K; Aoki S
    Int J Hematol; 2013 Feb; 97(2):275-9. PubMed ID: 23359301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease.
    Barker R; Kazmi F; Stebbing J; Ngan S; Chinn R; Nelson M; O'Doherty M; Bower M
    Eur J Nucl Med Mol Imaging; 2009 Apr; 36(4):648-52. PubMed ID: 19050873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
    Schnell R; Dietlein M; Schomäcker K; Kobe C; Borchmann P; Schicha H; Hallek M; Engert A
    Onkologie; 2008 Feb; 31(1-2):49-51. PubMed ID: 18268399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG PET/CT appearance of multicentric Castleman's disease mimicking lymphoma.
    Elboga U; Narin Y; Urhan M; Sahin E
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):142-4. PubMed ID: 22133346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET in malignant lymphoma: significance of positive findings.
    Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK; Wittekind C; Niederwieser D
    Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordant lymphoma consisting of mediastinal large B-cell lymphoma and nodular sclerosis Hodgkin lymphoma in the right supraclavicular lymph nodes: a case report.
    Zhang C; Yi Y; Chen C; Wang J; Liu Z
    Diagn Pathol; 2015 Dec; 10():215. PubMed ID: 26715530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary duodenal lymphoma: successful rituximab treatment and evaluation by FDG-PET.
    Tanaka F; Tominaga K; Ochi M; Yamada T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Uchida T; Oshitani N; Higuchi K; Arakawa T
    Hepatogastroenterology; 2007 Sep; 54(78):1658-61. PubMed ID: 18019688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy.
    Kalkanis D; Stefanovic A; Paes F; Escalon MP; Serafini A; Lossos IS
    Leuk Lymphoma; 2009 Jun; 50(6):904-11. PubMed ID: 19455459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hodgkin's and non-Hodgkin's lymphomas.
    Rademaker J
    Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and outcomes in patients with human immunodeficiency virus-negative, Castleman's disease: a single medical center study in Tunisia.
    Chabchoub I; Salah RB; Kallel R; Snoussi M; Frikha F; Marzouk S; Boudawara TS; Bahloul Z
    Rom J Intern Med; 2024 Mar; 62(1):20-32. PubMed ID: 37948573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice.
    Decaudin D; Marszak FB; Couturier J; Mathiot C; Martin A; Némati F; Lantz O; Santo Jd; Arnaud P; Bordier V; Vincent-Salomon A; Poupon MF
    Anticancer Drugs; 2006 Jul; 17(6):685-95. PubMed ID: 16917214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
    Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
    Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.